Finding better treatments for pediatric cancers with RAS mutations
Preventing Therapeutic Resistance in RAS-mutated Pediatric Cancers
This study is looking for better ways to treat kids with certain types of tumors that have a RAS mutation by using special medicines that target the cancer while being gentle on their growing bodies, so they can have a better chance of getting well.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-10781909 on NIH RePORTER |
What this research studies
This research focuses on developing targeted therapies for pediatric patients with RAS-mutated tumors, which are currently underserved by clinical trials. The approach involves using inhibitors to block specific signaling pathways that contribute to cancer growth, aiming to enhance the effectiveness of existing treatments while minimizing harm to normal developing tissues. By exploring new combinations of therapies, the research seeks to prevent resistance to treatment and improve outcomes for young patients. The study will utilize preclinical models to test these innovative strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients diagnosed with RAS-mutated tumors.
Not a fit: Patients without RAS mutations or those with advanced-stage cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for children with RAS-mutated cancers.
How similar studies have performed: While targeted therapies have shown promise in other cancer types, this specific approach for RAS-mutated pediatric cancers is novel and has not been extensively tested.
Where this research is happening
Bethesda, United States
- Henry M. Jackson Fdn for the Adv Mil/med — Bethesda, United States (Active)
Researchers
- Principal investigator: Kortum, Robert — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Kortum, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.